---
layout: post
title: "General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products; Guidance for Industry; Availability"
date: 2026-02-05 18:59:59 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-16076
original_published: 2022-07-27 00:00:00 +0000
significance: 8.00
---

# General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products; Guidance for Industry; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** July 27, 2022 00:00 UTC
**Document Number:** 2022-16076

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products." This guidance is intended to assist sponsors of investigational new drug applications (INDs) and applicants of new drug applications (NDAs), biologics license applications (BLAs), and supplements to such applications who are planning to conduct clinical studies in neonatal populations. This guidance finalizes the draft guidance of the same title issued on August 1, 2019.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/07/27/2022-16076/general-clinical-pharmacology-considerations-for-neonatal-studies-for-drugs-and-biological-products)
- API: https://www.federalregister.gov/api/v1/documents/2022-16076

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
